Substance P, insulinlike growth factor 1, and surface healing.
Lee
Catherine H
CH
Department of Ophthalmology and Visual Sciences, University of Wisconsin, 2870 University Ave, Suite 206, Madison, WI 53705, USA.
Whiteman
Amanda L
AL
Murphy
Christopher J
CJ
Barney
Neal P
NP
Taylor
Peter B
PB
Reid
Ted W
TW
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D019573:Epithelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000627:therapeutic use*; D015948:Keratoplasty, Penetrating / Q000009:adverse effects; D009883:Ophthalmic Solutions; D011112:Polymyxin B / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D013373:Substance P / Q000008:administration & dosage / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D013373:Substance P; D000068438:Brimonidine Tartrate; D007334:Insulin-Like Growth Factor I; D011112:Polymyxin B